Skip to main content

Share story

Security

WebSurface web attack surface discovery tool launched

WebSurface web attack surface discovery tool launched Image: 0ut3r.space
WebSurface is a script that automates discovery and triage of origin exposure for web infrastructure. It integrates subfinder for subdomain discovery, dnsx for DNS resolution, httpx for probing, naabu and nmap for scanning and fingerprinting, and gowitness for screenshots. The script enables visibility into external exposure using these components rather than million-dollar enterprise tooling. The pipeline first identifies subdomains and resolves their addresses. It then applies filters to exclude CDN and WAF infrastructure based on range checks, flags, CNAME patterns and other fingerprints. Only qualifying web-alive addresses that lack CDN characteristics advance to detailed port scanning and visual capture. Results from each execution are organized into a dedicated directory containing raw data, a summary report and an SQLite database. The tool provides signals about possible direct paths to backend services, open ports and certificate details that may indicate connections to public services. All indications are subject to manual verification because the classification methods rely on heuristics.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from 0ut3r.space and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.